Primary Biliary Cirrhosis Drug Market Report

China Primary Biliary Cirrhosis Drug Industry Market Research Report 2023-2029

  • POSTDATE：Sep 16, 2023
  • PAGES：187
  • REPORT CODE：GMM1800965
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the Primary Biliary Cirrhosis Drug industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • NGM Biopharmaceuticals, Inc

    • CymaBay Therapeutics, Inc

    • Intercept Pharmaceuticals, Inc

    • GlaxoSmithKline Plc

    • Enanta Pharmaceuticals, Inc

    • Dr Falk Pharma GmbH

    • Virobay Inc

    • AlbireoPharma

    • MediGene AG

    By Type:

    • MBX-8025

    • NGM-282

    • Budesonide

    • FFP-104

    • Others

    • GSK-2330672

    By Application:

    • Others

    • Hospital

    • Clinic

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Primary Biliary Cirrhosis Drug Market Overview 2018-2029

    • 1.1 China Primary Biliary Cirrhosis Drug Industry Development Overview

    • 1.2 China Primary Biliary Cirrhosis Drug Industry Development History

    • 1.3 China Primary Biliary Cirrhosis Drug Industry Market Size (2018-2029)

    • 1.4 China Primary Biliary Cirrhosis Drug Market Analysis by Type from Production Side

      • 1.4.1 China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of MBX-8025 (2018-2029)

      • 1.4.2 China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of NGM-282 (2018-2029)

      • 1.4.3 China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of Budesonide (2018-2029)

      • 1.4.4 China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of FFP-104 (2018-2029)

      • 1.4.5 China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of Others (2018-2029)

      • 1.4.6 China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of GSK-2330672 (2018-2029)

    • 1.5 China Primary Biliary Cirrhosis Drug Market Analysis by Application from Consumption End

      • 1.5.1 China Primary Biliary Cirrhosis Drug Sales Volume, Sales Value and Growth Rate of Others (2018-2029)

      • 1.5.2 China Primary Biliary Cirrhosis Drug Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)

      • 1.5.3 China Primary Biliary Cirrhosis Drug Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)

    • 1.6 China Primary Biliary Cirrhosis Drug Market Analysis by Region

      • 1.6.1 North China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

    Chapter 2 China Primary Biliary Cirrhosis Drug Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Primary Biliary Cirrhosis Drug Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Primary Biliary Cirrhosis Drug Market Status and Competition Analysis in 2023

      • 2.2.3 China Primary Biliary Cirrhosis Drug Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Primary Biliary Cirrhosis Drug Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Primary Biliary Cirrhosis Drug Industry Development

    Chapter 3 Primary Biliary Cirrhosis DrugIndustry Chain Analysis

    • 3.1 Primary Biliary Cirrhosis Drug Industry Chain

    • 3.2 Primary Biliary Cirrhosis Drug Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Primary Biliary Cirrhosis Drug Market

    • 3.3 Primary Biliary Cirrhosis Drug Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Primary Biliary Cirrhosis Drug Market

    Chapter 4 China Primary Biliary Cirrhosis Drug Market, by Type

    • 4.1 China Primary Biliary Cirrhosis Drug Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Primary Biliary Cirrhosis Drug Total Production Volume and Growth Rate from Production Side

    • 4.5 China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate, by Type

      • 4.5.1 China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of MBX-8025

      • 4.5.2 China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of NGM-282

      • 4.5.3 China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of Budesonide

      • 4.5.4 China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of FFP-104

      • 4.5.5 China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of Others

      • 4.5.6 China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of GSK-2330672

    Chapter 5 China Primary Biliary Cirrhosis Drug Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Primary Biliary Cirrhosis Drug Total Market Size and Growth Rate from Consumption End

    • 5.5 China Primary Biliary Cirrhosis Drug Market Size and Growth Rate, by Application

      • 5.5.1 China Primary Biliary Cirrhosis Drug Market Size and Growth Rate of Others

      • 5.5.2 China Primary Biliary Cirrhosis Drug Market Size and Growth Rate of Hospital

      • 5.5.3 China Primary Biliary Cirrhosis Drug Market Size and Growth Rate of Clinic

    Chapter 6 China Primary Biliary Cirrhosis Drug Market, by Region

    • 6.1 China Primary Biliary Cirrhosis Drug Production Volume and Production Value, by Region

    • 6.2 China Primary Biliary Cirrhosis Drug Sales Volume and Sales Value, by Region

    Chapter 7 North China Primary Biliary Cirrhosis Drug Market Analysis

    • 7.1 North China Primary Biliary Cirrhosis Drug Market, by Type

    • 7.2 North China Primary Biliary Cirrhosis Drug Market, by Application

    Chapter 8 Central China Primary Biliary Cirrhosis Drug Market Analysis

    • 8.1 Central China Primary Biliary Cirrhosis Drug Market, by Type

    • 8.2 Central China Primary Biliary Cirrhosis Drug Market, by Application

    Chapter 9 South China Primary Biliary Cirrhosis Drug Market Analysis

    • 9.1 South China Primary Biliary Cirrhosis Drug Market, by Type

    • 9.2 South China Primary Biliary Cirrhosis Drug Market, by Application

    Chapter 10 East China Primary Biliary Cirrhosis Drug Market Analysis

    • 10.1 East China Primary Biliary Cirrhosis Drug Market, by Type

    • 10.2 East China Primary Biliary Cirrhosis Drug Market, by Application

    Chapter 11 Northeast China Primary Biliary Cirrhosis Drug Market Analysis

    • 11.1 Northeast China Primary Biliary Cirrhosis Drug Market, by Type

    • 11.2 Northeast China Primary Biliary Cirrhosis Drug Market, by Application

    Chapter 12 Southwest China Primary Biliary Cirrhosis Drug Market Analysis

    • 12.1 Southwest China Primary Biliary Cirrhosis Drug Market, by Type

    • 12.2 Southwest China Primary Biliary Cirrhosis Drug Market, by Application

    Chapter 13 Northwest China Primary Biliary Cirrhosis Drug Market Analysis

    • 13.1 Northwest China Primary Biliary Cirrhosis Drug Market, by Type

    • 13.2 Northwest China Primary Biliary Cirrhosis Drug Market, by Application

    Chapter 14 Company Profiles

      • 14.1 NGM Biopharmaceuticals, Inc

        • 14.1.1 NGM Biopharmaceuticals, Inc Company Profile

        • 14.1.2 NGM Biopharmaceuticals, Inc Primary Biliary Cirrhosis Drug Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 CymaBay Therapeutics, Inc

        • 14.2.1 CymaBay Therapeutics, Inc Company Profile

        • 14.2.2 CymaBay Therapeutics, Inc Primary Biliary Cirrhosis Drug Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Intercept Pharmaceuticals, Inc

        • 14.3.1 Intercept Pharmaceuticals, Inc Company Profile

        • 14.3.2 Intercept Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 GlaxoSmithKline Plc

        • 14.4.1 GlaxoSmithKline Plc Company Profile

        • 14.4.2 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Enanta Pharmaceuticals, Inc

        • 14.5.1 Enanta Pharmaceuticals, Inc Company Profile

        • 14.5.2 Enanta Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 Dr Falk Pharma GmbH

        • 14.6.1 Dr Falk Pharma GmbH Company Profile

        • 14.6.2 Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Virobay Inc

        • 14.7.1 Virobay Inc Company Profile

        • 14.7.2 Virobay Inc Primary Biliary Cirrhosis Drug Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 AlbireoPharma

        • 14.8.1 AlbireoPharma Company Profile

        • 14.8.2 AlbireoPharma Primary Biliary Cirrhosis Drug Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 MediGene AG

        • 14.9.1 MediGene AG Company Profile

        • 14.9.2 MediGene AG Primary Biliary Cirrhosis Drug Market Performance

        • 14.9.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Primary Biliary Cirrhosis Drug Industry Research Conclusions

    • 15.2 Primary Biliary Cirrhosis Drug Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Primary Biliary Cirrhosis Drug Industry Market Size (2018-2029)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of MBX-8025 (2018-2029)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of NGM-282 (2018-2029)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of Budesonide (2018-2029)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of FFP-104 (2018-2029)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of Others (2018-2029)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume, Production Value and Growth Rate of GSK-2330672 (2018-2029)

    • Figure China Primary Biliary Cirrhosis Drug Sales Volume, Sales Value and Growth Rate of Others (2018-2029)

    • Figure China Primary Biliary Cirrhosis Drug Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)

    • Figure China Primary Biliary Cirrhosis Drug Sales Volume, Sales Value and Growth Rate of Clinic (2018-2029)

    • Figure North China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

    • Figure Central China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

    • Figure South China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

    • Figure East China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Primary Biliary Cirrhosis Drug Market Size and Growth Rate from 2018-2029

    • Figure Primary Biliary Cirrhosis Drug Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Primary Biliary Cirrhosis Drug Market Share by Type in 2018

    • Figure China Primary Biliary Cirrhosis Drug Market Share by Type in 2023

    • Figure China Primary Biliary Cirrhosis Drug Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of MBX-8025 (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of NGM-282 (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of Budesonide (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of FFP-104 (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of Others (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume and Growth Rate of GSK-2330672 (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Market Share by Application in 2018

    • Figure China Primary Biliary Cirrhosis Drug Market Share by Application in 2023

    • Figure China Primary Biliary Cirrhosis Drug Total Market Size and Growth Rate from Consumption End

    • Figure China Primary Biliary Cirrhosis Drug Market Size and Growth Rate of Others (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Market Size and Growth Rate of Hospital (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Market Size and Growth Rate of Clinic (2018-2023)

    • Table China Primary Biliary Cirrhosis Drug Production Volume by Region (2018-2023)

    • Table China Primary Biliary Cirrhosis Drug Production Volume Share by Region (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Production Volume Share by Region (2018-2023)

    • Table China Primary Biliary Cirrhosis Drug Production Value by Region (2018-2023)

    • Table China Primary Biliary Cirrhosis Drug Production Value Share by Region (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Production Value Share by Region (2018-2023)

    • Table China Primary Biliary Cirrhosis Drug Sales Volume by Region (2018-2023)

    • Table China Primary Biliary Cirrhosis Drug Sales Volume Share by Region (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Sales Volume Share by Region (2018-2023)

    • Table China Primary Biliary Cirrhosis Drug Sales Value by Region (2018-2023)

    • Table China Primary Biliary Cirrhosis Drug Sales Value Share by Region (2018-2023)

    • Figure China Primary Biliary Cirrhosis Drug Sales Value Share by Region (2018-2023)

    • Table North China Primary Biliary Cirrhosis Drug Production Volume by Type (2018-2023)

    • Table North China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Figure North China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Table North China Primary Biliary Cirrhosis Drug Sales Volume by Application (2018-2023)

    • Table North China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Figure North China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Table Central China Primary Biliary Cirrhosis Drug Production Volume by Type (2018-2023)

    • Table Central China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Figure Central China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Table Central China Primary Biliary Cirrhosis Drug Sales Volume by Application (2018-2023)

    • Table Central China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Figure Central China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Table South China Primary Biliary Cirrhosis Drug Production Volume by Type (2018-2023)

    • Table South China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Figure South China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Table South China Primary Biliary Cirrhosis Drug Sales Volume by Application (2018-2023)

    • Table South China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Figure South China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Table East China Primary Biliary Cirrhosis Drug Production Volume by Type (2018-2023)

    • Table East China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Figure East China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Table East China Primary Biliary Cirrhosis Drug Sales Volume by Application (2018-2023)

    • Table East China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Figure East China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Table Northeast China Primary Biliary Cirrhosis Drug Production Volume by Type (2018-2023)

    • Table Northeast China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Figure Northeast China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Table Northeast China Primary Biliary Cirrhosis Drug Sales Volume by Application (2018-2023)

    • Table Northeast China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Table Southwest China Primary Biliary Cirrhosis Drug Production Volume by Type (2018-2023)

    • Table Southwest China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Figure Southwest China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Table Southwest China Primary Biliary Cirrhosis Drug Sales Volume by Application (2018-2023)

    • Table Southwest China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Table Northwest China Primary Biliary Cirrhosis Drug Production Volume by Type (2018-2023)

    • Table Northwest China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Figure Northwest China Primary Biliary Cirrhosis Drug Production Volume Share by Type (2018-2023)

    • Table Northwest China Primary Biliary Cirrhosis Drug Sales Volume by Application (2018-2023)

    • Table Northwest China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Primary Biliary Cirrhosis Drug Sales Volume Share by Application (2018-2023)

    • Table NGM Biopharmaceuticals, Inc Company Profile

    • Table NGM Biopharmaceuticals, Inc Primary Biliary Cirrhosis Drug Revenue, Price and Gross (2018-2023)

    • Table CymaBay Therapeutics, Inc Company Profile

    • Table CymaBay Therapeutics, Inc Primary Biliary Cirrhosis Drug Revenue, Price and Gross (2018-2023)

    • Table Intercept Pharmaceuticals, Inc Company Profile

    • Table Intercept Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Revenue, Price and Gross (2018-2023)

    • Table GlaxoSmithKline Plc Company Profile

    • Table GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Revenue, Price and Gross (2018-2023)

    • Table Enanta Pharmaceuticals, Inc Company Profile

    • Table Enanta Pharmaceuticals, Inc Primary Biliary Cirrhosis Drug Revenue, Price and Gross (2018-2023)

    • Table Dr Falk Pharma GmbH Company Profile

    • Table Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Revenue, Price and Gross (2018-2023)

    • Table Virobay Inc Company Profile

    • Table Virobay Inc Primary Biliary Cirrhosis Drug Revenue, Price and Gross (2018-2023)

    • Table AlbireoPharma Company Profile

    • Table AlbireoPharma Primary Biliary Cirrhosis Drug Revenue, Price and Gross (2018-2023)

    • Table MediGene AG Company Profile

    • Table MediGene AG Primary Biliary Cirrhosis Drug Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US